MNPR vs VALN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MNPR · Monopar Therapeutics$71.42 ▲ 6.25%
VALN · Valneva$5.51 ▼ 2.31%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MNPR -14.0%
- VALN -38.0%
Head to head
| Metric | MNPR | VALN |
|---|---|---|
| Price | $71.42 | $5.51 |
| Change today | ▲ 6.25% | ▼ 2.31% |
| Market cap | $479.38M | $524.15M |
| Return, 3 months | -38.6% | +4.0% |
| Return, year to date | +9.4% | -37.5% |
| Return, 1 year | -11.8% | -36.8% |
| P/E (TTM) | – | – |
| P/B | 3.7 | 5.8 |
| P/E percentile vs own 5y | 9th | 91st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -27.7% |
| Net profit growth (YoY) | -116.6% | -169.3% |
| Gross margin | – | 16.4% |
| Operating margin | – | -80.4% |
| Net margin | – | -110.3% |
| Return on equity | -19.5% | -117.8% |
| Analyst target vs. price | +81.0% | +148.1% |
| Analyst buy share | 86% | 100% |
| RSI (14) | 44 | 45 |
| 30-day volatility | 58.2% | 51.4% |
| Max drawdown, 1 year | -46.5% | -60.1% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VALN is the largest of the group by market value.
- MNPR has returned the most over the past year.
- VALN has been the calmest stock over the last 30 days.